For adenocarcinoma, two types of strategies—known as tyrosine kinase inhibitor, for tumors carrying mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR), and crizotinib for tumors with the rearrangement of anaplastic lymphoma kinase (ALK)—are currently available as commercial personalized treatments [5, 7]. Here, ALK is linked to adenocarcinoma.